CRT in AF with right bundle branch block: is it effective?
Cardiac resynchronisation therapy in atrial fibrillation patients with right bundle branch block is not a uniform indication. A person may have symptoms from uncontrolled ventricular rates, systolic heart failure, or both, and each problem responds to a different combination of medicines, rhythm control, and device therapy. The key issue is whether delayed or ineffective ventricular activation is making the heart work inefficiently enough for resynchronisation to add value.
The practical answer is conditional rather than negative. Conventional CRT has stronger evidence when the baseline QRS is wide because of left bundle branch block, while benefit with right bundle branch block is less consistent and is especially uncertain in patients whose atrial fibrillation is continuously present. QRS duration, ejection fraction, the amount of expected right ventricular pacing, ventricular rate control, and the cause of heart failure all shape the decision.
Why right bundle branch block changes the CRT question
CRT combines right and left ventricular pacing to change the sequence of ventricular activation. In left bundle branch block, the left ventricle is usually activated late, so advancing its activation can make the two ventricles contract more together. That electrical and mechanical rationale is less convincing in a classic right bundle branch block, where the right ventricle is delayed but the left ventricle activates relatively early.
Right bundle branch block is nevertheless a surface pattern, not a complete map of conduction. Some patients have additional left-sided intraventricular delay, extensive scar, or conduction disease extending beyond the right bundle. Biventricular pacing may improve coordination in selected cases, but routine use for every patient with atrial fibrillation and right bundle branch block is not supported by the same trial evidence as left bundle branch block.
Selection should also avoid equating a wide QRS with a high likelihood of sudden death. Risk assessment must include ventricular arrhythmia risk, ischaemic disease, and functional status. The journal's account of bedside risk stratification describes how repolarisation alternans may inform that assessment, while such testing remains complementary to the CRT decision.
Who may benefit in atrial fibrillation
The most plausible CRT candidate has symptomatic heart failure with reduced ejection fraction, usually at or below 35%, despite appropriate guideline-directed medical therapy. A QRS of at least 150 milliseconds with right bundle branch block provides a stronger rationale than a narrower complex, although the supporting evidence is weaker. CRT is not expected to rescue advanced ventricular dysfunction caused mainly by extensive myocardial scar.
Persistent atrial fibrillation changes both the evidence and the programming requirements. Near-continuous atrial fibrillation can prevent reliable delivery of biventricular pacing if the intrinsic ventricular rate is high or conduction is irregular. Before implantation or upgrade, the team should establish whether adequate rate control is achievable and whether sinus rhythm is likely to return; a rhythm-control plan and a pacing strategy should complement rather than compete with each other.
Useful assessment includes a 12-lead ECG, echocardiography, medication and adherence review, coronary evaluation where indicated, and interrogation of any existing pacemaker or defibrillator. In an upgrade, recorded pacing burden, ventricular thresholds, atrial arrhythmia burden, and heart-failure trends can reveal whether the patient has already been exposed to harmful right ventricular pacing. These data are more informative than an isolated referral diagnosis.
Interpreting the evidence
Major trials such as CARE-HF and COMPANION provide the foundation for CRT benefit in symptomatic systolic heart failure, but many participants had sinus rhythm and left bundle branch block. Trials that include atrial fibrillation or patients receiving conventional pacing have produced less decisive results. For example, B-CONVINCED tested CRT in patients with an indication for pacing, yet its small atrial fibrillation subgroup could not resolve the wider uncertainty. Subgroup findings therefore require cautious application.
Apparent conflicts often shrink when the comparison question is made explicit. Broad trials of de novo CRT, studies of upgrading from right ventricular pacing, and series involving atrial fibrillation enrol different populations and use different endpoints. The journal's discussion of matching study populations captures why clinical relevance depends on aligning morphology, rhythm, QRS duration, and device indication rather than averaging them together.
Clinicians should ask whether an apparent response is a change in symptoms, exercise capacity, ejection fraction, or a hard outcome such as hospitalisation. Echocardiographic synchrony measures can vary by operator and have limited reproducibility, so improvement in one measurement should not outweigh clinical deterioration. Much of the published evidence is observational, leaving selection bias and treatment differences as important alternative explanations.
AF, ventricular pacing, and device selection
Atrial fibrillation exposes a device to changing intrinsic rates, irregular R-R intervals, and variable conduction. Depending on programming, a CRT system may deliver ventricular pulses inconsistently if its lower-rate and upper-rate behaviour is unsuited to the arrhythmia burden. Interrogation should confirm ventricular capture, appropriate pacing percentage, atrial sensing behaviour, and the timing of left ventricular pacing relative to intrinsic activation.
If rapid ventricular responses persist despite tolerated medical therapy, AV node ablation can create a dependable paced rhythm and allow biventricular pacing to be assessed properly. The procedure is irreversible and can affect haemodynamics and future options, so it should follow multidisciplinary review rather than be used simply to guarantee device function. Rhythm restoration remains an option for selected patients, but successful cardioversion can alter pacing requirements and programming.
Follow-up should use symptom review, device interrogation, and structured heart-failure assessment. Clinicians should look for recurrent rapid rates, pauses, inappropriate shocks where a defibrillator is present, and a rising percentage of competitive or ineffective ventricular activation. Medication changes should be coordinated with the programmer because beta-blockers, rate-control drugs, and rhythm-control agents can alter capture margins and device behaviour.
Biventricular pacing versus alternative strategies
Biventricular CRT remains the established resynchronisation option, but it is not the only way to improve activation. His bundle pacing and left bundle branch area pacing seek to use the native conduction system, potentially producing more physiological ventricular activation than a right ventricular-paced left ventricular lead. In patients with right bundle branch block, conduction-system pacing is of particular interest, although comparative evidence for hard outcomes remains developing.
Device choice also includes CRT with pacing only or defibrillation capability, lead position, programming ranges, and expected longevity. A defibrillator may be appropriate for selected patients with ischaemic cardiomyopathy or additional ventricular-arrhythmia risk, but it also brings shocks, replacement procedures, and anxiety that must be discussed. Shared decisions should incorporate age, comorbidity, frailty, goals, and the likelihood of meaningful benefit.
Specialist evaluation may include advanced imaging or selected noninvasive synchrony studies, but none replaces a coherent clinical assessment. Current reviews and themed collections in Journal of Arrhythmia resources can support continuing education for clinicians comparing these approaches as the evidence evolves.
Making the decision in Australian practice
Australian practice adds practical layers to this decision. Patients in Sydney, Melbourne, Brisbane, and Perth may be reviewed in tertiary electrophysiology or heart-failure services, while people in regional, rural, and remote areas can face long travel distances and fragmented follow-up. Shared care between cardiologists, electrophysiologists, general practitioners, pharmacists, and device clinics is therefore more than administrative convenience.
The local device market includes public-hospital purchasing, private electrophysiology services, Medicare reimbursement for eligible procedures, and private health insurance that may affect out-of-pocket costs. Device selection should consider warranty support, programmer availability, and replacement pathways as well as clinical evidence. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002, the TGA assesses and monitors devices sold in Australia.
Everyday care matters as much as procedural planning. Patients often manage several medicines through morning doses, pharmacy repeats, and routines built around work, commuting, exercise, and family responsibilities; a missed anticoagulant or beta-blocker can alter both arrhythmia and device performance. Telehealth and remote device transmission can support follow-up, but privacy remains governed by the Privacy Act 1988 and the My Health Records Act 2012, including who can access uploaded information.
Australian guidelines and specialist pathways should be integrated with international evidence rather than treated as separate rules. Anticoagulation remains based on thromboembolic and bleeding risk, not on the presence of CRT, and many oral anticoagulants are listed on the Pharmaceutical Benefits Scheme. Before an elective procedure, clinicians should verify renal function, medication adherence, and the plan for anticoagulant interruption with the prescribing team while avoiding unnecessary disruption.
The strongest case for CRT in atrial fibrillation with right bundle branch block is a patient with persistent systolic heart failure, a substantially wide QRS, inadequate left ventricular synchrony or a high expected pacing burden, and a rhythm strategy that permits reliable biventricular pacing. The weakest case is a narrow QRS, a well-controlled ventricular rate, advanced irreversible myocardial disease, and no demonstrable pacing or synchrony problem.
Arrange a formal heart-failure and electrophysiology review with the ECG, recent echocardiogram, medication list, rhythm history, and any device interrogation in hand. Record the expected benefit, uncertainty arising from right bundle branch block and atrial fibrillation, device options, anticoagulation plan, and follow-up arrangements. That transparent process turns CRT from a blanket answer into a defensible, patient-specific choice.